Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DA-3002 in Short Children Borns SGA.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronological Age ≥ 4~* Before the adolescence, Tuner stage I (breast)~* Height \<3rd percentile for age~* Normal thyroid function~Exclusion Criteria:~* Growth hormone was administered for 12 months or longer in the past~* Treated with estrogen or adrenal androgens for 12 months or longer in the past~* Malignancy, CNS Trauma, Psychiatric Disorder~* endocrine and/or metabolic disorders~* growth failure caused by other disorders

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- DA-3002 (Type: EXPERIMENTAL): 1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
- Genotropin® (Type: ACTIVE_COMPARATOR): 1.44 IU (0.48mg)/kg/week of Genotropin is injected for 52 weeks by changing injecting areas(six or seven times per week).
- Non-treatment control group (Type: OTHER): After no treatment for 26 weeks, 1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).

Based on this trial design, predict the completion outcome and termination type (if applicable).